🇺🇸 FDA
Patent

US 9663790

Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression

granted A61KA61K48/0058A61K48/0066

Quick answer

US patent 9663790 (Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression) held by The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center
Grant date
Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K48/0058, A61K48/0066, A61P, A61P3/04